Abstract
Acute onset of severe psychiatric symptoms or regression may occur in children with premorbid neurodevelopmental disorders, although typically developing children can also be affected. Infections or other stressors are likely triggers. The underlying causes are unclear, but a current hypothesis suggests the convergence of genes that influence neuronal and immunological function. We previously identified 11 genes in Pediatric Acute-Onset Neuropsychiatry Syndrome (PANS), in which two classes of genes related to either synaptic function or the immune system were found. Among the latter, three affect the DNA damage response (DDR): PPM1D, CHK2, and RAG1. We now report an additional 17 cases with mutations in PPM1D and other DDR genes in patients with acute onset of psychiatric symptoms and/or regression that were classified by their clinicians as PANS or another inflammatory brain condition. The genes include clusters affecting p53 DNA repair (PPM1D, ATM, ATR, 53BP1, and RMRP), and the Fanconi Anemia Complex (FANCE, SLX4/FANCP, FANCA, FANCI, and FANCC). We hypothesize that defects in DNA repair genes, in the context of infection or other stressors, could lead to an increase in cytosolic DNA in immune cells triggering DNA sensors, such as cGAS-STING and AIM2 inflammasomes. These findings could lead to new treatment strategies.
Competing Interest Statement
J.L.C. has received lecturing fees from Otsuka Pharma Scandinavia, Janssen-Cilag AB and H. Lundbeck AB.
Funding Statement
National Institute of Child Health and Human Development NIH/NICHD; P30 HD071593 the National Institute of Mental Health, R21MH131740; the Janice C. Blanchard Family Fund; the iPS Cell Research for Ryan Stearn Fund; J.L.C Swedish Research Council (Grant No. 2019-06082); EU H2020; ImmunAID; MOODSTRATIFICATION grant; the Dutch Heart Foundation; Gullstrand Fellowship; the Neuroimmune Foundation; Lucile Packard Foundation for Children's Health; the Dollinger Biomarker Core; Stanford Spark Fellowship; the Neuroimmune Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the Albert Einstein College of Medicine gave ethical approval for this work (protocol number 2022-14636)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We included an additional case; case 17, which has a pathogenic mutation in FANCC. This lends further support to our hypothesis that mutations in Fanconi complex genes increases the risk of acute neuropsychiatric decompensation in children
Data availability statement
Variants reported in this paper will be submitted to ClinVar. WES data on case 10 will be made available at GenBank ®
